The Actual Disagreement

Joyous prescribes low-dose ketamine taken daily, at doses below those producing significant dissociation. This practice uses higher doses at defined intervals, with a support person present. The two rest on different theories: the daily model treats ketamine as a maintenance medication like an antidepressant, while the session model treats it as an intervention that opens a plasticity window you then work within. Both are defensible positions and they lead to different programs.

• Daily low-dose treats ketamine as continuous maintenance medication
• Periodic dosing treats it as an intervention plus an integration window
• Dissociation is deliberately avoided in the daily model and expected here
• Support-person requirements follow directly from that difference
• Neither is a scam; they are different bets on the same pharmacology

Where the Evidence Sits

This is the part worth weighing. The randomized trials that established ketamine as an antidepressant used periodic administration at doses producing noticeable psychoactive effects. Berman, Zarate, Murrough and Feder all follow that pattern. Daily sub-perceptual dosing has substantially less randomized evidence behind it. That does not mean it does not work, and patients do report benefit; it means the two protocols are not equally evidenced and you should know which one you are choosing.

• Landmark trials used periodic dosing at psychoactive levels
• Daily low-dose protocols have a thinner randomized evidence base
• Reported patient benefit is not the same thing as trial evidence
• The synaptogenesis account fits periodic dosing more naturally
• Whether dissociation is necessary for benefit remains genuinely unresolved

What Each Model Suits

Rather than argue for one, it is more useful to say which constraints point where. Some patients genuinely cannot arrange a support person or clear a day, and for them a daily low-dose program may be the only realistic option. That is a legitimate reason to choose it.

• Daily low-dose suits patients who cannot arrange sessions or a sitter
• Daily low-dose avoids dissociation, which some patients will not accept
• Session-based suits patients wanting the protocol the trials used
• Session-based pairs with therapy in the plasticity window afterward
• Session-based requires clearing a day and having a sober adult present

Questions to Ask Either Provider

These apply to us as much as to anyone else, and a practice that will not answer them plainly is telling you something.

• Who is the prescribing physician, and will you see the same one throughout?
• What happens if you do not respond after an adequate course?
• What are the exclusion criteria, and are they assessed before payment?
• How are drug interactions reviewed, drug by drug or by category?
• Is there a real medical evaluation, or a form that approves nearly everyone?
• What is the total cost of a full course including maintenance?

How This Practice Runs

Stated plainly so it can be compared against whatever else you are considering. Tovani is the higher-cost option of the two models and it is worth understanding what that buys before choosing it.

• Physician-led throughout, with Dr. Ben Soffer, DO, rather than a rotating panel
• Validated screening scored before any consultation or payment
• Interaction review drug by drug against a physician-reviewed directory
• Extended booking windows including 12:30 PM and 5:00 PM appointments
• A sober support person required for every session, without exception
• Patients who do not screen safely are declined rather than accepted